Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors

Am J Hematol. 2017 Feb;92(2):220-221. doi: 10.1002/ajh.24608.

Authors

Hayan Jouni¹, Mary C Aubry², Martha Q Lacy³, S Vincent Rajkumar³, Shaji K Kumar³, Robert L Frye¹, Joerg Herrmann¹

Affiliations

¹ Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
³ Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

PMID: 27859518
DOI: 10.1002/ajh.24608

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biopsy
Boron Compounds / administration & dosage
Boron Compounds / adverse effects*
Cardiotoxicity
Echocardiography
Glycine / administration & dosage
Glycine / adverse effects
Glycine / analogs & derivatives*
Heart Failure / diagnosis*
Heart Failure / etiology*
Humans
Magnetic Resonance Imaging
Male
Multiple Myeloma / complications
Multiple Myeloma / drug therapy
Protease Inhibitors / administration & dosage
Protease Inhibitors / adverse effects*

Substances

Antineoplastic Agents
Boron Compounds
Protease Inhibitors
ixazomib
Glycine